Heart transplantation

Journal of Intensive Care Medicine

Volumn 19, Issue 1, 2004, Pages 3-12

  Poston, Robert S ^a,b   Griffith, Bartley P ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b Division of Cardiac Surgery   (United States)

Author keywords

Heart transplantation; Immunosuppression; Review; Surgical technique

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ASSISTED CIRCULATION; CHRONIC GRAFT REJECTION; HEART FAILURE; HEART PRESERVATION; HEART TRANSPLANTATION; HUMAN; INCIDENCE; ORGAN DONOR; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; GRAFT REJECTION; HEART DISEASE; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MORTALITY; ORGAN PRESERVATION; PERIOPERATIVE PERIOD;

GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; ORGAN PRESERVATION; PERIOPERATIVE CARE; TRANSPLANTATION CONDITIONING;

EID: 2342445419     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066603259012     Document Type: Review

References (85)

1. Poston RS, Hussain S, Source D, et al. Blood stream infection in the VAD patient: rationale for transplantation. J Heart Lung Transplant. In press.
2. UNOS Data Request number 2/26/2003-16.
3. Mancini D, LeJemtel T, Aaronson K. Peak VO(2): a simple yet enduring standard. Circulation. 2000;101(10):1080-1082.
4. Based on data from the Organ Procurement and Transplantation Network as of 1/31/03. Retrieved from www.optn.org/data
5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
6. Cazeau S, Leclercq C, Lavergne T. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. The Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. N Engl J Med. 2001;344:873-880.
7. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
8. Cope JT, Kaza AK, Reade CC, et al. A cost comparison of heart transplantation versus alternative operations for cardiomyopathy. Ann Thorac Surg. 2001;72(4):1298-1305.
9. Michael K. Pasque mathematic modeling and cardiac surgery J Thorac Cardiovasc Surg. 2002;123:617-620.
10. AJ Bank, SH Mir, DQ Nguyen, et al. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Ann Thorac Surg. 2000;69:1369-1374.
11. Rose EA and the REMATCH Investigators. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443.
12. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1339-1367.
13. Tepaske R, Velthuis H, Oudemans-van Straaten HM, et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet. 2001;358(9283):696-701.
14. von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of S. aureus bacteremia. N Engl J Med. 2000;344(1):11-5.
15. Itescu S, Burke E, Ankersmit J, et al. Immunologic effects of left ventricular assist device support. Ann Thorac Surg. In press.
16. Registry of the ISHLT for 2001. Retrieved from http://www.ishlt.org
17. Joergensen EO. Spinal man after brain death. Acta Nerohir (Vien). 1973;28:259.
18. Novitsky D, Cooper D, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain dead potential organ donors. Transplantation. 1987;43:852.
19. Zaroff JG, Rosengard BR, Armstrong WF, et al. Maximizing use of organs recovered from the cadaver donor: cardiac recommendations(1). March 28-29, 2001. J Heart Lung Transplant. 2002;21(11):1153-1160.
20. Jacobbi LM, Montgomery RA, Bartlett ST, et al. Novel machine preservation (MP) protocol improves outcome of expanded criteria kidneys. Transplantation. 2002;74:35, abstract #52.
21. Hassanein WH, Zellos L, Tyrrell TA, et al. Continuous perfusion of donor hearts in the beating state extends preservation time and improves recovery of function. J Thorac Cardiovasc Surg. 1998;116(5):821-830.
22. Poston RS, Ennen M, Pollard J, Hoyt EG, Robbins RC. Ex vivo gene therapy prevents chronic graft vascular disease in cardiac allografts. J Thorac Cardiovasc Surg. 1998;116:128-139.
23. Land W, Zweler JL. Prevention of reperfusion-induced, free radical-mediated acute endothelial injury by superoxide dismutase as an effective tool to delay/prevent chronic renal allograft failure: a review. Transplant Proc. 1997;29(6):2567-2568.
24. Hosenpud JD, Edwards EB, Lin H-M, Daily OP. Influence of HLA matching on thoracic transplant outcomes: an analysis from the UNOS/ISHLT* Thoracic Registry. Circulation. 1996;94:170-174.
25. Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation: the Collaborative Transplant Study. N Engl J Med. 1994;330:816-819.
26. rd. Defining the role of aprotinin in heart transplantation. Ann Thorac Surg. 1996;62(3):670-674.
27. Ereth MH, Nuttall GA, Klindworth JT. Does the platelet-activated clotting test (HemoSTATUS®) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg. 1997;85(2):259-264.
28. Ng KF, Lo JW. The development of hypercoagulability state, as measured by thromb-elastography, associated with intraoperative surgical blood loss. Anaesth Intensive Care. 1996;24(1):20-25.
29. Gamel AE, Yonan NA, Grant S, et al. Orthotopic cardiac transplanation: a comparison of standard and bicaval Wythenshawe techniques. J Thorac Cardiovasc Surg. 1995;109:721-730.
30. Novitzky D, Wicomb WN, Cooper DK, et al. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. Ann Thorac Surg. 1986;41(5):520-524.
31. Moon MR, Bolger AF, DeAnda A, Komeda M, et al. Septal function during left ventricular unloading. Circulation. 1997;95:1320-1327.
32. Bittner HB, Chen EP, Biswas SS, et al. Right ventricular dysfunction after cardiac transplantation: primarily related to status of donor heart. Ann Thorac Surg. 1999;68(5):1605-1611.
33. Arafa OE, Geiran OR, Andersen K, et al. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. Ann Thorac Surg. 2000;70(5):1587-1593.
34. Vogel M, Schmidt MR, Kristiansen SB, et al. Validation of myocardial acceleration during isovolumic contraction as a novel noninvasive index of right ventricular contractility: comparison with ventricular pressure-volume relations in an animal model. Circulation. 2002;105(14):1693-1699.
35. RL Kormos TA, Gasior A, Kawai, et al. Transplant candidates clinical status rather than hemodynamics determines the need for right ventricular support. J Thorac Cardiovasc Surg. 1996;111:773-783.
36. West LJ, Pollock-Barziv SM, Dipchand AI, et al. ABO-incompatible heart transplantation in infants. N Engl J Med. 2001;344(11):793-800.
37. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64:1120-1125.
38. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplant. Circulation. 1999;100:II;229-35.
39. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18(7):701-706.
40. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation. 2002;10s:1214-1219.
41. Bach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nature Med. 1997;3:196-204.
42. Greif R, Akça O, Horn E-P, et al. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med. 2000;342:161-167.
43. Risnes I, Abdelnoor M, Baksaas ST, et al. Sternal wound infections in patients undergoing open heart surgery: randomized study comparing intracutaneous and transcutaneous suture techniques. Ann Thorac Surg. 2001;72:1587-1591.
44. Tergulia S, Airbotariu R, Colovai AI, et al. New strategies for early diagnosis of allograft rejection. Transplantation. 1997;64:842-847.
45. Narula J, Acio ER, Narula N, et al. Annexin V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7(12):1347-1352.
46. Marie PY, Angioi M, Carteaux JP. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. J Am Coll Cardiol. 2001;37(3):825-831.
47. Ciliberto GR, Mascarello M, Gronda E, et al. Acute rejection after heart transplantation: noninvasive echocardiographic evaluation. J Am Coll Cardiol. 1994;23(5):1156-1161.
48. Iberer F, Grasser B, Schreier G, et al. Introducing a new clinical method for noninvasive rejection monitoring after heart transplantation to clinical practice: analysis of paced intramyocardial electrograms. Transplant Proc. 1998;30(3):895-899.
49. Barlow CW, Moon MR, Green GR, et al. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis. Transpl Int. 2001;14(4):234-239.
50. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55(7):603-613.
51. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5(6):686-693.
52. Baran DA, Segura L, Kushwaha S, et al. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant. 2001;20:59-70.
53. Poston R, McCurry K, Griffith B. Kidney transplantation following heart transplantation: effects on cardiac outcome. J Heart Lung Transplant. 2002;21(1):102.
54. Coopersmith CM, Brennan DC, Miller B, et al. Renal transplantation following previous heart, liver, and lung transplantation: an 8-year single-center experience. Surgery. 2001;130(3):457-462.
55. Taylor DO, Barr ML, Radovancevic B, et al. A randomised, multicenter comparison of TAC and CsA immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with TAC. J Heart Lung Transplant. 1999;18(4):336.
56. Allison A, Eugui EM. Mycophenolate mofetil (RS-61443): mode of action and effects on graft rejection. In: Thompson AW, Starzl TE, eds. Immunosuppressive Drugs: Developments in Anti-Rejection Therapy. London: Edward Arnold; 1994:144.
57. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation. 1998;66:507-515.
58. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening after balloon catheter injury and allows endothelial replacement. Transplantation. 1995;59:655.
59. Poston RS, Billingham M, Hoyt EG, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 1999;100(1):67-74.
60. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation. 2000;70(6):969-975.
61. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
62. Keogh A. Progression of graft vessel disease in cardiac allograft recipients is significantly reduced by sirolimus immunotherapy: 6-month results from a phase 2, open-label study. Abstract #431. Am J Transpl. 2002;2(suppl 3):246.
63. Tuzcu EM, Schoenhagen P, Starling RC, et al. Impact of everolimus on allograft vasculopathy: the SDZ RAD/heart intravascular ultrasound study. J Heart Lung Transplant. 2002;21(1):68.
64. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immuno-suppression. Lancet. 2000;355(9201):376-377.
65. Hausen B, Gummert J, Berry GJ, et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)- rapamycin. Transplantation. 2000;69(4):488-496.
66. Johnson MR, Mullen GM, O'Sullivan EJ, et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol. 1994;74:261-226.
67. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361(9368):1502-1510.
68. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
69. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992;255(5048):1125-1127.
70. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
71. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000;342:613-619.
72. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation. 1996;62:1565-1570.
73. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation. 1993;55:766-772.
74. Pierson RN III, Miller GG. Late graft failure. Lessons from clinical and experimental thoracic organ transplantation. Graft. 2000;3:88.
75. Valantine H, Rickenbacker P, Kemna M, et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation. 2001;103(17):2144- 2152.
76. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987;19:19.
77. Lim TT, Liang DH, Botas J, et al. Role of compensatory enlargement and shrinkage in transplant coronary artery disease. Serial intravascular ultrasound study. Circulation. 1997;95(4):855-859.
78. Hollenberg S, Klein L, Parrillo J, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation. 104:3091-3096.
79. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
80. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561.
81. Holweg CT, Baan CC, Balk AH, et al. The transforming growth factor-beta1 codon 10 gene polymorphism and accelerated graft vascular disease after clinical heart transplantation. Transplantation. 2001;71(10):1463-1467.
82. Baan CC, Balk AH, Holweg CT, et al. Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. J Heart Lung Transplant. 2000;19(9):866-872.
83. Cecka JM, Terasaki PI, eds. Clinical Transplants 1995. Los Angeles: UCLA Tissue Typing Laboratory; 1995.
84. Taylor PM, Rose ML, Yacoub MH, et al. Induction of vascular adhesion molecules during rejection of human cardiac allografts. Transplantation. 1992;54:541.
85. McKechnie RS, Rubenfire M. The role of inflammation and infection in coronary artery disease: a clinical perspective. Curr J Rev. 2002;11(1):32-34.